Sign in

    Hanxing Gao • Guggenheim Partners

    Hanxing Gao is an analyst at Guggenheim Partners specializing in equity research; however, publicly available information does not confirm their exact title, sector or company coverage, performance record, or career credentials at this time. There are no identifiable details regarding Gao's track record, company focus, or prior professional experience with reputable investment platforms or ranking authorities. Due to the lack of reliable data from both LinkedIn and reputable financial databases, specifics relating to their tenure, professional registrations, or industry recognitions remain unavailable. Further research using proprietary or internal databases may be required to obtain a comprehensive professional profile for Hanxing Gao.

    Hanxing Gao's questions to Neumora Therapeutics Inc (NMRA) leadership

    Hanxing Gao's questions to Neumora Therapeutics Inc (NMRA) leadership • Q3 2024

    Question

    Hanxing Gao of Guggenheim Partners, on behalf of Yatin Suneja, sought confirmation on whether discontinuation rates in the KOASTAL studies were tracking in the 5% to 10% range, as previously guided.

    Answer

    Robert Lenz, Head of Research and Development, declined to provide a specific figure but stated that the team was 'encouraged' by the discontinuation rates observed in the study. He confirmed that full details would be provided with the top-line results.

    Ask Fintool Equity Research AI